CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Masha Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hos…. Hauptthemen laut MEDLINE: RNA, Circular, Drug Resistance, Neoplasm, Y-Box-Binding Protein 1, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Key Research and Development Program of Hunan Province of China, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality. Resistance to platinum-based chemotherapy, such as cisplatin, significantly limits treatment efficacy. Circular RNAs (circRNAs) have emerged as key regulators of cancer progression and chemotherapy resistance due to their stable structure, which protects them from degradation. In this study, we focus on circKIAA0182, a circRNA identified as highly expressed in cisplatin-resistant NSCLC cells through profiling. We explore its role in cell proliferation, migration, invasion, apoptosis, and cisplatin resistance. Our findings show that circKIAA0182 promotes cisplatin resistance and tumor progression in NSCLC, in vitro and in vivo. Furthermore, we discovered that circKIAA0182 may interact with the RNA-binding protein YBX1, potentially mediating its oncogenic and cisplatin-resistant functions. The biological role of circKIAA0182 presents a promising target for developing therapeutic strategies to overcome NSCLC progression and cisplatin resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, PR China; Institute…
- Department of Geriatrics, Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, 410008, PR China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, PR China.
- The Affiliated Children's Hospital of Xiangya School of Medicine, Central South University (Hunan Children's Hospital), Changsha, 410007, PR China.
- Department of Neonatology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, 214023, PR China; Department of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan Univers…
Förderung
- Key Research and Development Program of Hunan Province of China
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Huang, M., Sun, J., Jiang, Q., Zhao, X., Huang, H., Lei, M., Jiang, S., Yuan, F., & Liu, Z. (2025). CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217494
Vancouver
Huang M, Sun J, Jiang Q, Zhao X, Huang H, Lei M, et al. CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217494
BibTeX
@article{Huang2025,
author = {Huang, Masha and Sun, Jingyi and Jiang, Qingqing and Zhao, Xin and Huang, Hanxue and Lei, Mengrong and Jiang, Shilong and Yuan, Fuqiang and Liu, Zhaoqian},
title = {CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217494}
}
EUVIMED